The combinational treatment between the selective antimetastatic agent, sodium-transrutheniumtetrachloridedimethylsulfoxideimidazole, Na[trans-RuCI4(DMSO)lm], and the cytotoxic drug 5-fluorouracil (5-FU) on primary tumor growth and on the survival time of experimental tumors results in an effect significantly greater than that of each single agent used alone either with the solid metastasizing MCa mammary carcinoma of the CBA mouse or with the lymphocytic leukemia P388 and its platinum resistant P388/DDP subline. Thus the inorganic compound Na[transRuCI4(DMSO)Im], known for its potent and selective antimetastatic effects, positively interacts with the antitumor action of an organic anticancer agent such as 5-FU on both a solid metastasizing tumor and a tumor of lymphoproliferative type. In particular, the effects of the combinational treatment on the survival time of tumor bearing mice seem to be related to the selective antimetastatic activity of the ruthenium complex that joins the potent cytotoxicity of 5-FU for the tumor. Moreover, these data show that Na[trans-RuCI4(DMSO)lm] is almost as effective on the subline of P388 made resistant to cisplatin as it was on the parental line.
INTRODUCTION
On the wave of enthusiasm for the positive results obtained with platinum complexes , the search for novel anticancer agents has brought to the characterization of new compounds based on complexes of transition metals. Of these, ruthenium complexes attracted the interest of many groups because of some promising chemical characteristic and pharmacologic activity in different models of experimental tumors2-4. One of the last compounds that have been discovered is certainly Na[transRuCI4(DMSO)Im], a drug of the future endowed with a particular effectiveness against solid tumor metastasesS, 6. Considering that anticancer chemotherapy is practically always done by drugs active on primitive tumors, we thought it worthwhile testing the effects of a combination with the selective antimetastatic agent Na[trans-RuCI4(DMSO)lm] and a cytotoxic drug of a large use such as 5-fluorouracil (5-FU). The purpose of the study was that of measuring the existence of a combination of effects on the primary and on the metastatic tumor, with a significant amelioration of life-time expectancy. The study was made either on a solid metastasizing tumor, the MCa mammary carcinoma of the CBA mouse 7 or with a tumor of lymphoproliferative type, the P388 lymphocytic leukemia and its platinum resistant P388/DDP subline. The experimental condition used was identical to that reported in Figure 3 . has no negative effects on the antitumor activity of 5-FU and to some extent, it potentiates the effects of 5-FU. The effects of the combinational treatment on the survival time of mice with MCa mammary carcinoma should be attributed to the antimetastatic activity of the ruthenium complex. The reduction of metastases by the ruthenium complex, besides the selective conditions in which it has often been tested,o, is thus therapeutically useful even in the present experimental model, a paradigm that does not emphasize the role of distant metastases for survival in that the presence
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